Latest Insider Transactions at Sangamo Therapeutics, Inc (SGMO)
This section provides a real-time view of insider transactions for Sangamo Therapeutics, Inc (SGMO). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of SANGAMO THERAPEUTICS, INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of SANGAMO THERAPEUTICS, INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 03
2022
|
John Markels |
BUY
Open market or private purchase
|
Direct |
6,784
+17.28%
|
$20,352
$3.69 P/Share
|
|
Jun 01
2022
|
H Stewart Parker |
BUY
Open market or private purchase
|
Direct |
5,000
+9.31%
|
$15,000
$3.6 P/Share
|
|
Apr 29
2022
|
Scott B. Willoughby SVP, GEN. COUNSEL & SECRETARY |
SELL
Payment of exercise price or tax liability
|
Direct |
140
-0.15%
|
$560
$4.15 P/Share
|
|
Apr 25
2022
|
Prathyusha Duraibabu SVP, CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
662
-0.76%
|
$2,648
$4.83 P/Share
|
|
Apr 25
2022
|
Jason D. Fontenot SVP, Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
826
-0.79%
|
$3,304
$4.83 P/Share
|
|
Apr 24
2022
|
Scott B. Willoughby SVP, GEN. COUNSEL & SECRETARY |
SELL
Payment of exercise price or tax liability
|
Direct |
3,976
-4.19%
|
$15,904
$4.7 P/Share
|
|
Mar 25
2022
|
Prathyusha Duraibabu SVP, CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
345
-0.39%
|
$1,725
$5.75 P/Share
|
|
Feb 25
2022
|
Robert Carey |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+25.93%
|
-
|
|
Feb 25
2022
|
Kenneth J. Hillan |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+25.93%
|
-
|
|
Feb 25
2022
|
John Markels |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+32.72%
|
-
|
|
Feb 25
2022
|
James R Meyers |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+25.93%
|
-
|
|
Feb 25
2022
|
H Stewart Parker |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+22.24%
|
-
|
|
Feb 25
2022
|
Saira Ramasastry Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+25.93%
|
-
|
|
Feb 25
2022
|
Karen L. Smith |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+24.65%
|
-
|
|
Feb 25
2022
|
Joseph S Zakrzewski Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+17.08%
|
-
|
|
Feb 25
2022
|
Sandy Macrae PRESIDENT, CEO AND DIRECTOR |
BUY
Grant, award, or other acquisition
|
Direct |
224,000
+30.06%
|
-
|
|
Feb 25
2022
|
Sandy Macrae PRESIDENT, CEO AND DIRECTOR |
SELL
Payment of exercise price or tax liability
|
Direct |
49,890
-14.37%
|
$249,450
$5.9 P/Share
|
|
Feb 25
2022
|
David Mark Mc Clung EVP, Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
59,400
+24.31%
|
-
|
|
Feb 25
2022
|
David Mark Mc Clung EVP, Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,610
-3.54%
|
$23,050
$5.9 P/Share
|
|
Feb 25
2022
|
Prathyusha Duraibabu SVP, CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
41,000
+31.84%
|
-
|
|
Feb 25
2022
|
Prathyusha Duraibabu SVP, CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
3,474
-6.91%
|
$17,370
$5.9 P/Share
|
|
Feb 25
2022
|
Jason D. Fontenot SVP, Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
45,100
+30.25%
|
-
|
|
Feb 25
2022
|
Jason D. Fontenot SVP, Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,248
-9.59%
|
$31,240
$5.9 P/Share
|
|
Feb 25
2022
|
Rolf Andrew Ramelmeier EVP, Technical Operations |
BUY
Grant, award, or other acquisition
|
Direct |
54,000
+27.49%
|
-
|
|
Feb 25
2022
|
Rolf Andrew Ramelmeier EVP, Technical Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
12,388
-12.29%
|
$61,940
$5.9 P/Share
|
|
Feb 25
2022
|
Robert J. Schott SVP, Head of Development |
BUY
Grant, award, or other acquisition
|
Direct |
41,000
+35.18%
|
-
|
|
Feb 25
2022
|
Scott B. Willoughby SVP, GEN. COUNSEL & SECRETARY |
BUY
Grant, award, or other acquisition
|
Direct |
41,000
+30.19%
|
-
|
|
Feb 25
2022
|
Scott B. Willoughby SVP, GEN. COUNSEL & SECRETARY |
SELL
Payment of exercise price or tax liability
|
Direct |
1,566
-2.83%
|
$7,830
$5.9 P/Share
|
|
Feb 12
2022
|
Robert J. Schott SVP, Head of Development |
SELL
Payment of exercise price or tax liability
|
Direct |
5,463
-13.66%
|
$27,315
$5.76 P/Share
|
|
Dec 28
2021
|
Biogen Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
2,764
-0.01%
|
$22,112
$8.51 P/Share
|
|
Dec 27
2021
|
Biogen Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
600
-0.0%
|
$4,800
$8.56 P/Share
|
|
Dec 23
2021
|
Biogen Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
81,187
-0.34%
|
$649,496
$8.55 P/Share
|
|
Dec 09
2021
|
Biogen Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
23,660
-0.1%
|
$189,280
$8.56 P/Share
|
|
Dec 08
2021
|
Biogen Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
75,814
-0.31%
|
$606,512
$8.64 P/Share
|
|
Dec 07
2021
|
Biogen Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
52,178
-0.21%
|
$417,424
$8.52 P/Share
|
|
Dec 02
2021
|
Biogen Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
1,874
-0.01%
|
$14,992
$8.51 P/Share
|
|
Dec 01
2021
|
Biogen Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
730
-0.0%
|
$5,840
$8.52 P/Share
|
|
Nov 26
2021
|
Biogen Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
28,884
-0.12%
|
$231,072
$8.6 P/Share
|
|
Oct 29
2021
|
Scott B. Willoughby SVP, GEN. COUNSEL & SECRETARY |
SELL
Payment of exercise price or tax liability
|
Direct |
140
-0.26%
|
$1,120
$8.12 P/Share
|
|
Aug 13
2021
|
Scott B. Willoughby SVP, GEN. COUNSEL & SECRETARY |
BUY
Grant, award, or other acquisition
|
Direct |
7,500
+12.08%
|
-
|
|
Jun 25
2021
|
David Mark Mc Clung EVP, Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
11,525
-8.18%
|
$138,300
$12.02 P/Share
|
|
Jun 11
2021
|
Prathyusha Duraibabu SVP, CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
7,500
+13.08%
|
-
|
|
Apr 25
2021
|
Prathyusha Duraibabu SVP, CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
662
-1.62%
|
$7,282
$11.71 P/Share
|
|
Apr 25
2021
|
Jason D. Fontenot SVP, Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
811
-1.28%
|
$8,921
$11.71 P/Share
|
|
Mar 25
2021
|
Prathyusha Duraibabu SVP, CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
345
-0.84%
|
$4,140
$12.27 P/Share
|
|
Mar 23
2021
|
Gary Loeb EVP, General Counsel & Sec. |
SELL
Open market or private sale
|
Direct |
17,524
-6.06%
|
$227,812
$13.15 P/Share
|
|
Mar 23
2021
|
Gary Loeb EVP, General Counsel & Sec. |
BUY
Exercise of conversion of derivative security
|
Direct |
11,981
+10.63%
|
$131,791
$11.02 P/Share
|
|
Feb 25
2021
|
Robert Carey |
BUY
Grant, award, or other acquisition
|
Direct |
8,200
+26.11%
|
-
|
|
Feb 25
2021
|
Kenneth J. Hillan |
BUY
Grant, award, or other acquisition
|
Direct |
8,200
+26.11%
|
-
|
|
Feb 25
2021
|
John Markels |
BUY
Grant, award, or other acquisition
|
Direct |
8,200
+38.32%
|
-
|